注：本產(chǎn)品僅用于科研，不可用于臨床
Verteporfin試劑簡介
Verteporfin (CL 318952) 是一種用于光動力療法的光敏劑，用于消除與年齡相關(guān)的黃斑變性等疾病相關(guān)的眼內(nèi)異常血管。 Verteporfin 是一種 YAP 抑制劑，可破壞 YAP-TEAD 相互作用。Verteporfin 可以誘導細胞凋亡 (apoptosis)。Verteporfin 是一種自噬 (autophagy) 抑制劑，通過抑制自噬小體形成，在早期阻斷自噬。
Verteporfin試劑簡介生物活性
Verteporfin (CL 318952) is a photosensitizer for photodynamic therapy to eliminate the abnormal blood vessels in the eye associated with conditions such as age-related macular degeneration. Verteporfin is a YAP inhibitor which disrupts YAP-TEAD interactions. Verteporfin induces cell apoptosis[1]. Verteporfinis an autophagy inhibitor that blocks autophagy at an early stage by inhibiting autophagosome formation
| IC50 & Target | IC50: YAP-TEAD interaction | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 體外研究 (In Vitro) | Verteporfin is specifically selected by PDX-cell screening. The concentrations to cause 50% growth inhibition (GI50) for PhLO, PhLH, and PhLK are 228 nM, 395 nM, and 538 nM, respectively, whereas GI50 for ALL-1, TCC-Y/sr, and NPhA1 are 3.93 µM, 2.11 µM, and 5.61 µM, respectively. GSH significantly reduces the sensitivity of 2 out of 3 PDX cells to verteporfin. Verteporfin reduces the mitochondrial membrane potential in PDX cells[1]. Verteporfin reduces the PTX-resistance on HCT-8/T cells by inhibiting YAP expression and combination therapy with verteporfin and NSC 125973 shows synergism on inhibition of YAP and cytotoxicity to HCT-8/T[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 體內(nèi)研究 (In Vivo) | Verteporfin (10 mg/kg, c.s.c.) and BMS-354825 significantly reduces the leukemia cell ratio, and combined therapy further reduced the number of leukemia cells in the spleen[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. | ||||||||||||||||
| 分子量 | 718.79 | ||||||||||||||||
| 性狀 | Solid | ||||||||||||||||
| Formula | C82H84N8O16 | ||||||||||||||||
| CAS 號 | 129497-78-5 | ||||||||||||||||
| 中文名稱 | 維替泊芬 | ||||||||||||||||
| 運輸條件 | Room temperature in continental US; may vary elsewhere. | ||||||||||||||||
| 儲存方式 | 4°C, protect from light *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light) | ||||||||||||||||
| 溶解性數(shù)據(jù) | In Vitro: DMSO : 100 mg/mL (139.12 mM; Need ultrasonic) DMF : 10 mg/mL (13.91 mM; ultrasonic and warming and heat to 60°C) 配制儲備液
* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液；一旦配成溶液，請分裝保存，避免反復(fù)凍融造成的產(chǎn)品失效。 In Vivo: 請根據(jù)您的實驗動物和給藥方式選擇適當?shù)娜芙夥桨?。以下溶解方案都請先按?nbsp;In Vitro 方式配制澄清的儲備液，再依次添加助溶劑： ——為保證實驗結(jié)果的可靠性，澄清的儲備液可以根據(jù)儲存條件，適當保存；體內(nèi)實驗的工作液，建議您現(xiàn)用現(xiàn)配，當天使用； 以下溶劑前顯示的百
|
采購中心
